However, a major challenge is that many patients undergoing immunotherapy develop resistance and experience rapid relapse, largely due to the interactions between GI tumours and the TIME, which are mediated by immunosuppressive elements like programmed cell death ligand 1-positive (PD-L1+) exosomes [8,9]. The gene discussed is CD274; the disease is digestive system neoplasm.